Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Pyxis Oncology Inc (PYXS)

Pyxis Oncology Inc (PYXS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 227,160
  • Shares Outstanding, K 59,466
  • Annual Sales, $ 0 K
  • Annual Income, $ -73,790 K
  • EBIT $ -69 M
  • EBITDA $ -72 M
  • 60-Month Beta 1.27
  • Price/Sales 12.84
  • Price/Cash Flow N/A
  • Price/Book 1.61

Options Overview Details

View History
  • Implied Volatility 181.89% ( -54.29%)
  • Historical Volatility 191.97%
  • IV Percentile 53%
  • IV Rank 26.50%
  • IV High 656.63% on 12/27/23
  • IV Low 10.70% on 07/15/24
  • Put/Call Vol Ratio 0.04
  • Today's Volume 5,122
  • Volume Avg (30-Day) 2,639
  • Put/Call OI Ratio 0.10
  • Today's Open Interest 19,528
  • Open Int (30-Day) 15,129

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.32
  • Number of Estimates 5
  • High Estimate -0.28
  • Low Estimate -0.38
  • Prior Year -0.33
  • Growth Rate Est. (year over year) +3.03%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.91 +8.64%
on 11/21/24
5.39 -61.50%
on 11/11/24
-1.61 (-43.61%)
since 10/21/24
3-Month
1.91 +8.64%
on 11/21/24
5.39 -61.50%
on 11/11/24
-1.56 (-42.84%)
since 08/21/24
52-Week
1.35 +53.70%
on 11/24/23
6.85 -69.71%
on 02/27/24
+0.65 (+45.10%)
since 11/21/23

Most Recent Stories

More News
Stocks Rise Before the Open With U.S. Economic Data in Focus, Nvidia Slips on Disappointing Forecast

December S&P 500 E-Mini futures (ESZ24) are up +0.20%, and December Nasdaq 100 E-Mini futures (NQZ24) are up +0.09% this morning as investors looked ahead to a raft of U.S. economic data that could provide...

TGT : 121.92 (+0.16%)
EVTC : 36.27 (+4.10%)
NVDA : 143.71 (-1.49%)
DE : 435.85 (+7.63%)
PYXS : 2.13 (-44.24%)
INTU : 673.98 (+3.59%)
SNOW : 170.39 (+31.96%)
JD-.LN : 95.440 (-15.50%)
NQZ24 : 20,720.75 (-0.14%)
FN : 232.56 (+2.77%)
CPRT : 56.43 (+1.82%)
QCOM : 156.56 (+1.48%)
Pyxis Oncology Reports Promising Phase 1 Clinical Data for PYX-201 in Multiple Solid Tumors and Announces Collaboration with Merck to Evaluate Combination Therapy

PYX-201 shows promising efficacy and safety in solid tumors, with expansion trials set to begin in 2025.Quiver AI SummaryPyxis Oncology announced positive preliminary results from a Phase 1 dose escalation...

PYXS : 2.13 (-44.24%)
Pyxis Oncology Announces Favorable Preliminary PYX-201 Clinical Phase 1 Part 1 Data

PYXS : 2.13 (-44.24%)
Pyxis Oncology Provides Corporate Update and Reports Financial Results for Third Quarter 2024

PYXS : 2.13 (-44.24%)
Pyxis Oncology to Host In-Person (NYC) and Virtual Investor Event on Wednesday, November 20, 2024, to Present Preliminary Data from the Phase 1 Dose Escalation Trial of PYX-201

PYXS : 2.13 (-44.24%)
New FDA Designations Accelerate Progress in Pancreatic Cancer Treatments: A Year in Review

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:PYXS),(NASDAQ:AZN),(NYSE:LLY),(NASDAQ:MRUS) EQNX::TICKER_END

ONCY : 0.9800 (-1.85%)
ONC.TO : 1.39 (-0.71%)
PYXS : 2.13 (-44.24%)
AZN : 63.54 (+0.54%)
LLY : 742.91 (-1.39%)
MRUS : 44.50 (+3.66%)
New FDA Designations Accelerate Progress in Pancreatic Cancer Treatments: A Year in Review

/PRNewswire/ -- USA News Group - Since September 2022, the US Food and Drug Administration (FDA) has seen new treatments for pancreatic cancer that are worthy...

ONC.TO : 1.39 (-0.71%)
ONCY : 0.9800 (-1.85%)
PYXS : 2.13 (-44.24%)
AZN : 63.54 (+0.54%)
LLY : 742.91 (-1.39%)
MRUS : 44.50 (+3.66%)
Breakthroughs in Pancreatic Cancer Treatment: How FDA Designations are Changing the Game

USA News Group – Since September 2022, the US Food and Drug Administration (FDA) has seen new treatments for pancreatic cancer that are worthy of further investigation or approval. Known as one of the...

ONCY : 0.9800 (-1.85%)
ONC.TO : 1.39 (-0.71%)
PYXS : 2.13 (-44.24%)
AZN : 63.54 (+0.54%)
LLY : 742.91 (-1.39%)
MRUS : 44.50 (+3.66%)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Pyxis Oncology, Inc. (NASDAQ: PYXS)

/PRNewswire/ -- Levi & Korsinsky announces that it has commenced an investigation of Pyxis Oncology, Inc. (NASDAQ: PYXS) concerning possible breaches of...

PYXS : 2.13 (-44.24%)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Pyxis Oncology, Inc. (NASDAQ: PYXS)

/PRNewswire/ -- Levi & Korsinsky announces that it has commenced an investigation of Pyxis Oncology, Inc. (NASDAQ: PYXS) concerning possible breaches of...

PYXS : 2.13 (-44.24%)

Business Summary

Pyxis Oncology Inc. is a preclinical oncology company. It focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers. The company's product pipeline includes antibody drug conjugate and monoclonal antibody. Pyxis Oncology Inc. is based in CAMBRIDGE, Mass.

See More

Key Turning Points

3rd Resistance Point 4.66
2nd Resistance Point 4.49
1st Resistance Point 4.15
Last Price 2.13
1st Support Level 3.64
2nd Support Level 3.47
3rd Support Level 3.13

See More

52-Week High 6.85
Fibonacci 61.8% 4.75
Fibonacci 50% 4.10
Fibonacci 38.2% 3.45
Last Price 2.13
52-Week Low 1.35

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar